Life science companies in England will be offered “flexible and confidential commercial arrangements” when negotiating market access for certain innovative medicines, with the possibility of market access up to four years earlier than at present for genuinely “transformative” new drugs, says the UK government in its long awaited response to the Accelerated Access Review produced by Professor Sir John Bell in October 2016.
Under the plans, which basically uphold most of the proposals in the AAR, a handful of selected innovations – drugs,...
